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Abstract 
Purpose To determine the validity of a self-administered questionnaire (Acro-CQ) developed to 
systematically assess the presence, type and time of onset of acromegaly comorbidities. 
Methods This is a cross-sectional  study;  105  acromegaly patients and 147 controls with other types of 
pituitary adenoma, referred to a specialized Italian Center, autonomously compiled Acro-CQ in an 
outpatient clinical setting. To test its reliability in a different setting, Acro-CQ was administered via 
mail to 78 patients with acromegaly and 100 with other pituitary adenomas, referred to a specialized US 
Center. Data obtained from questionnaires in both set- tings were compared with medical records (gold 
standard). Results Demographics of patients and controls from both countries were similar. In both 
settings, >95 % of the questionnaires were completely filled; only one item was missed in the others. 
Concordance with medical record was excellent (k > 0.85) for most of the items, independently from 
the way of administration, patient age, gender and nationality, pituitary adenoma type and disease 
activity. 
Conclusions Acro-CQ is an inexpensive, highly accepted from patients and reliable tool recommended 
to expedite systematic collection of relevant clinical data in acromeg- aly at diagnosis, to be replicated 
at follow-ups. This tool may guide a targeted, cost-effective management of com- plications. Moreover, 
it could be applied to retrieve data  for survey studies in both acromegaly and other pituitary adenomas, 
as information is easily and rapidly accessible for statistical analysis. 
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Introduction 
Acromegaly  is  a  rare  disorder  resulting  from     chronic hypersecretion of growth hormone (GH), 
mostly caused by a pituitary adenoma [1]. It mainly occurs sporadically, but may be seen in familial 
diseases [2]. It is characterized by dysmorphic facial and body features, anatomic and func- tional 
alterations of internal organs, metabolic, neoplastic and cardiovascular diseases (CVD), neurological 
symp- toms and hypopituitarism secondary to adenoma mass effect, overall responsible for high 
morbidity and mortality [1, 3, 4]. Because of the disease complexity and the vari- able physician 
approach to patients, it is difficult to obtain  a systematic assessment of the numerous complications 
induced by GH hypersecretion—whose risk and severity are related to disease duration and not always 
reversed by biochemical control—and its treatments [3, 5] and to rep- licate it at the various follow-ups. 
Moreover, because of economic restrictions imposed to the healthcare systems,    a more personalized, 
cost-effective screening of complica- tions would be very important in these patients. 
Based on these premises, our study aimed at assessing the validity of a questionnaire purposely 
developed to sys- tematically assess, at diagnosis and during follow-up, the type, prevalence and time of 
onset of relevant disorders typically associated with acromegaly and its treatments, to be used in the 
clinical practice for a patient-targeted cost- effective management. 
 
Materials and methods 
 
Two hundred and fifty-two patients, 105 with acromegaly due to a GH-secreting adenoma (cases; 66 F; 
mean age 59.0 ± 14.8 years) and 147 with other types of pituitary adenoma (controls; 87 prolactinomas 
and 60 non-function- ing adenomas, NFA; 80 F; mean age 55.0 ± 16.1 years) consecutively  referred  to  
the  Division  of Endocrinology, Diabetes and Metabolism, University of Turin (Italy) from November 
2012 to May 2014, were evaluated.  
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The diagnosis of acromegaly was based on the pres- ence of suggestive clinical features associated with 
MRI evidence of a pituitary adenoma, elevated age-adjusted IGF-I levels and nadir GH after oral 
glucose load >1 μg/l [5]. Disease was considered controlled in the presence of normal age- and gender-
adjusted serum IGF-I levels and random GH < 1 μg/l during treatment and cured when these criteria 
were fulfilled after treatment discontinua- tion [5]. Prolactinoma was  diagnosed  in  the  presence  of 
elevated serum prolactin levels and MRI evidence of pituitary adenoma, after excluding other causes of 
hyper- prolactinemia and mixed GH-/PRL-secreting tumors. Prolactin levels at diagnosis, together with 
clinical, bio- chemical and radiological findings and (in some cases) response to therapy with dopamine 
agonists,  contrib-  uted to differential diagnosis between prolactinomas and NFA [6]. Remission was 
defined as serum prolactin level in the normal range during medical treatment; patients were considered 
cured when  prolactin  levels  were  in the normal range after treatment discontinuation.  NFA was 
defined as MRI-detected pituitary adenoma in the absence of hormone hypersecretion [7]. Patients with 
hypopituitarism were adequately substituted with hormo- nal replacement therapy. 
Patients were asked to fill, in an outpatient setting, a self-administered, 22-item questionnaire (Acro-
CQ), pur- posely developed to systematically assess the presence    of (1) omorbidities typically 
associated with acromegaly and its treatment, including metabolic (glucose, lipid and bone 
metabolism), CVD and neoplastic disorders; intestinal diverticulosis/diverticulitis; gallbladder and 
kidney  stones; and goiter and carpal tunnel syndrome and (2) family his- tory of pituitary adenoma. For 
each comorbidity, patients were also asked to indicate their age at diagnosis, and for neoplasia, the type 
and location (Fig. 1). 
The choice of comorbidities to be investigated by the questionnaire was made by a team of 
neuroendocrinolo- gists based on their clinical practice and expert reviews/ international guidelines: 
Disorders typically associated  with acromegaly and deserving treatment to prevent long- term 
morbidity and mortality were included [3, 5, 8]. To improve patient understanding and compliance, we 
formu- lated simple and direct questions, using the easiest possible terms. 
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To determine Acro-CQ validity, the same data collected through questionnaire’s administration were 
retrieved from medical records—considered the gold standard—together with information on adenoma 
size at diagnosis, hormonal parameters at diagnosis and follow-up (to determine dis- ease activity and 
the adequacy of replacement therapy in case of hypopituitarism), the presence of residual adenoma and 
type and duration of the various treatments. 
With regard to associated disorders (―comorbidities‖), acromegaly patients had been screened at 
diagnosis and follow-up according to international guidelines [9], while controls had been evaluated 
only in the presence of sug- gestive symptoms and/or risk factors. Based on the estab- lished promoting 
role of chronic GH hypersecretion on the development of systemic disorders and the mean reported 
delay in acromegaly diagnosis (2.5–10 years on     average) [8], comorbidities diagnosed ≤5 years 
before   acromegaly were arbitrarily defined ―complications‖, and those affect- ing ≥10 patients were 
considered ―common‖. 
Hypertension was defined as a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure 
≥90 mmHg or the use of antihypertensive drugs. International criteria were applied for the diagnosis of 
impaired fasting glucose, impaired glucose tolerance and diabetes [10], dyslipidemia [11], osteopenia 
and osteoporosis [12]. The diagnosis of thyroid hyperplasia/goiter was established by ultrasound 
examination. 
To confirm the concordance between self-reported dis- ease and medical record in a different 
geographical setting, the study was extended to 178 patients, 78 with acromegaly and 100 with other 
pituitary adenomas, referred to the Pitu- itary Center of the Johns Hopkins University Hospital, Bal- 
timore (USA). At this purpose, Acro-CQ, originally formu- lated in Italian, was translated in English 
and reviewed by  a native speaker. Patients were contacted by mail, filled the questionnaire at home and 
returned it by mail using prepaid stamped envelops. 
The questionnaire was returned by 35 acromegaly patients (20 F; mean age 56.1 ± 11.6 years) and 40 
patients with other types of pituitary adenoma (controls; 21 F; mean age 59.3 ± 11.0 years; 14 
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prolactinomas and 26 NFA). Patients’ main demographics and clinical characteristics are summarized 
in Table 1. 
The study was approved by the Hospital Ethics Commit- tees of both Turin University and Johns 
Hopkins Univer- sity. Only patients able to autonomously read and fill the questionnaire and give their 
written informed consent to participate in the study were included. 
 
Statistical  analysis 
 
Prevalence of comorbidities was defined for cases and con- trols; in patients with acromegaly, we also 
calculated the prevalence, temporal distribution and median time interval between diagnosis and 
complication’s onset. Inter-group differences were assessed using Chi-square test or Fisher’s exact test 
(n ≤ 5); a p value <0.05 was considered statisti- cally significant. Multivariate logistic regression 
analysis, adjusted for gender and age at time of response to the ques- tionnaire, was performed to test 
differences in prevalence of comorbidities between groups; odds ratios were also cal- culated. The 
concordance between clinical record and ques- tionnaire was evaluated by Cohen’s Kappa coefficient 
[13]: For k ≤ 0.6, logistic regression was performed to assess  the influence of gender and age at 
evaluation (independent predictors of the model) on questionnaire response. Gender differences in 
answering to the questionnaire were calcu- lated by Fisher’s exact test. 
Statistical analysis was performed with STATA Statis- tical Software, release 12 (StataCorp LP, 
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The groups of patients with acromegaly and controls from Italy and USA were homogeneous for gender 
and age dis- tribution, at diagnosis of pituitary adenoma and at evalua- tion (Table 1). 
Neoplasia was more frequently associated with acro- megaly than other pituitary adenomas, although 
the statistical significance was reached only for gastroin- testinal  (p  <  0.004;  p  <  0.0001  for  
colonic   polyposis) and genitourinary neoplasia (p < 0.01) (Supplementary Table 1). The great majority 
of the tumors, except for hematologic ones, were benign, as detailed in Table 2. 
Acromegaly patients were at higher risk of metabolic abnormalities (impaired glucose tolerance; 
IGT/diabetes; dyslipidemia; osteopenia/osteoporosis), hypertension, hyper- trophic/dilatative and 
valvular cardiac disorders (p < 0.0005), but not for arrhythmias, ischemic events or aneurysms. Gall- 
bladder (p < 0.0001) and kidney stones (p < 0.004), intesti- nal diverticulosis (p < 0.0001), goiter (p < 
0.0001),   obstructive  sleep  apnea  (p  = 0.004)  and  carpal  tunnel syndrome (p < 0.0001) were also 
more frequent in acromegaly. The majority of complications appeared soon after acromegaly diagnosis 
(median ≤ 5.5 years) (Supplementary Table 1).  In 
both groups, patients typically developed gallbladder and kidney stones during SSA treatment 
(Supplementary Table 1). 
Familial history of pituitary adenoma was present  in four patients with acromegaly and one with NFA 
(4/5 were males). 
In the Italian cohort, questionnaires were completely filled by 98.9 % of acromegaly patients, and by 
95.7 % of the controls; only one item (typically diverticulosis, IGT/ diabetes and genitourinary benign 
neoplasia) was missing in incomplete questionnaires (Supplementary Table 2). 
Concordance between questionnaire  and  medical record was good or excellent (k > 0.6) for all items 
in both groups, except for genitourinary neoplasia (k = 0.54), CVD (k = 0.45) and dyslipidemia (k = 
0.51), underreported    in acromegaly. Logistic regression analysis showed a higher number of 
mismatches in males for genitourinary benign neoplasia, but no gender differences for CVD and 
  8 
dyslipi- demia. Concordance between questionnaire and medical record was negatively associated with 
age at the time of questionnaire’s compilation for genitourinary benign neoplasia, CVD and IGT. 
The administration of Acro-CQ to the Baltimore cohort confirmed the excellent rate of e-questionnaire  
completion (97 % in acromegaly and 97.7 % in controls of the returned questionnaires were completely 
filled), as well the high concordance between questionnaire and medical record, being k > 0.7 for all 
items except for thyroid hyperplasia   (k = 0.4), underreported in the control group. 
 
Discussion 
We present the results of a cross-sectional study assessing the validity of Acro-CQ, the first 
questionnaire developed to systematically assess at diagnosis, and monitor during follow-up, the 
presence of comorbidities typically associ- ated with acromegaly, thus improving patient management. 
Acromegaly is a chronic disease associated with a large number of comorbidities, typically presenting 
in the first years after diagnosis and not always reversed after disease control, responsible for a 
significant increase in morbidity, impairment of the quality of life and high mortality rate [1, 3–5]. At 
the same time, due to the disease complexity and variable physi- cian approach to patients, it is 
currently difficult to obtain a systematic evaluation at diagnosis to be replicated at follow- ups. 
Moreover, because of economic restrictions imposed on the healthcare systems, a more personalized 
monitoring of complications would be extremely important for a cost-effec- tive patient management. 
For this purpose, historical informa- tion retrieved from patients through validated tools could be 
extremely useful, especially for those with limited available medical  data  evaluated  in  specialized  
medical  centers geographically far from their residence and referring physicians. 
According to our data, Acro-CQ is a valid tool for an easy, comprehensive and inexpensive assessment 
and mon- itoring of acromegaly comorbidities. Indeed, the patient acceptance rate and concordance 
with medical record are very high, independently from patient age, gender, lan- guage and clinical 
setting. The success of the questionnaire is likely based on the clear format, close-ended questions with 
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dichotomous answers formulated using an easy and straightforward language [14, 15]. When 
questionnaire was mailed, the percentage of return was overall satisfactory (42 %). Providing patients 
with prepaid stamped envelops may have increased the rate of response [16]. 
On the other hand, a minor limitation to the clinical application of the questionnaire at each follow-up 
visits could be the relatively long time needed to completely fill the questionnaire in patients with many 
comorbidities. 
Moreover, being the questionnaire self-administered,  we demonstrated for the first time that patients 
with acromegaly and, more generally, pituitary adenomas are highly aware about disorders associated 
with their condition. 
Finally, using both questionnaires and medical records, the prevalence data of a great variety of 
disorders were retrieved from a large and homogeneous cohort of patients with acromegaly, for the first 
time compared to patients with other types of pituitary adenoma. Data analysis dem- onstrated a 
significantly higher prevalence of  metabolic and cardiovascular disorders, as well as thyroid hyperpla- 
sia, carpal tunnel syndrome and intestinal diverticulosis in acromegaly than in other pituitary adenomas, 
confirming percentages obtained from previous studies considering acromegaly patients per se, or in 
comparison with healthy subjects [3, 17–22]. On the contrary, the prevalence of obstructive sleep apnea 
was lower in our cohort than previ- ously reported (19 vs. 60–90 %) [3], underling the impor- tance of 
formal assessment of sleep disorders, as symptoms leading to polysomnography investigation are 
frequently underestimated. 
Independently of the type of pituitary adenoma, a strong association was found between SSA therapy 
and the devel- opment of gallstones (confirming the literature data [23]) and kidney stones. Several 
mechanisms for which SSA contribute to gallstones formation have been postulated, leading to 
increased bile concentration and lithogenic changes in its composition, together with physical condi- 
tions favoring micro-crystal precipitation and stone for- mation. Conversely, mechanisms that could 
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cause SSA to predispose to kidney stones formation remain unknown, as chronic administration of SSA 
apparently does not impact on calcium metabolism [24]. 
Whether the risk of cancer and related mortality is increased by GH hypersecretion is debated [3,  20,  
21,  25]. We found that the prevalence of neoplasia in acro- megaly was not significantly higher than in 
other   pituitary adenomas, except for gastrointestinal and genitourinary tumors (Supplementary Table 
1), being the great majority of these lesions benign (Table 2). Rates of thyroid hyper- plasia, 
gastrointestinal and genitourinary benign tumors were in line with the literature [3, 21, 26], but we did 
not observe the increased risk of malignant transformation of thyroid nodules and intestinal polyps 
reported by larger cohort studies and meta-analysis [3, 20, 21, 25], possibly due to the smaller sample 
size. 
In conclusion, we recommend Acro-CQ for an easy, inexpensive, reproducible and comprehensive 
assessment of relevant comorbidities associated with acromegaly (but also with other pituitary 
adenomas), at diagnosis and follow-up visits, to guide a patient-targeted and cost-effective manage- 
ment. Because it takes a relatively long time to completely fill the questionnaire in patients with many 
comorbidities, physicians could decide in more complex patients, espe- cially those requiring very 
frequent visits, to administer the Acro-CQ only during selected follow-up visits. 
The Acro-CQ can also be used to retrieve data for sur- vey studies in the field of pituitary disorders, as 
clinical information is easily and rapidly accessible for statistical analysis. 
The application of this tool to larger cohorts of patients (i.e., multicenter studies) would be extremely 
useful to bet- ter determine the validity of the suggested tool, both in the clinical and research settings. 
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